Emily O'Driscoll

Sep 18, 2024 | biorxiv.org | Sakshi Arora |Jonathan Lang |Beverly L. Davidson |Emily O'Driscoll

AbstractRecombinant adeno-associated virus (rAAV) vectors are an effective and well-established tool in the growing gene therapy field, with five approved AAV-mediated gene therapies already on the market and numerous more in clinical trials. However, manufacturing rAAV vectors is an expensive, timely, and labor-intensive process that limits the commercial use of AAV-mediated gene therapies.